2-ethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one | 120782-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-ethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 2-ethyl-6-methoxy-3,4-dihydro-2H-naphthalen-1-one
• CAS: 120782-11-8
• 化学式: C₁₃H₁₆O₂
• 分子量: 204.269
• InChiKey: JFMSKLQAUFINLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 在 sodium tetrahydroborate 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 0.67h， 生成 2-Ethyl-3,4-dihydro-6-methoxynaphthalene
  参考文献：
  名称：

  WO2007/67615

  摘要：

  公开号：
• 作为产物：
  描述：

  碘乙烷 、 6-甲氧基-1-萘满酮 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 12.33h， 以15%的产率得到2-ethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
  [FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。

  公开号：

  WO2021003295A1

文献信息

• [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2021003295A1

  公开（公告）日：2021-01-07

  The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。
• Fluoride Anions in Self-Assembled Chiral Cage for the Enantioselective Protonation of Silyl Enol Ethers
  作者：Sushovan Paladhi、Yidong Liu、B. Senthil Kumar、Min-Jung Jung、Sang Yeon Park、Hailong Yan、Choong Eui Song

  DOI：10.1021/acs.orglett.7b01429

  日期：2017.6.16

  The potential of Song’s chiral oligoethylene glycols (oligoEGs) as catalysts was explored in the enantioselective protonation of trimethylsilyl enol ethers in combination with alkali metal fluoride (KF and CsF) and in the presence of a proton source. Highly enantioselective protonations of various silyl enol ethers of α-substituted tetralones were achieved, producing chiral α-substituted tetralones

  Song的手性低聚乙二醇（oligoEGs）作为催化剂的潜力已在三甲基甲硅烷基烯醇醚与碱金属氟化物（KF和CsF）结合以及质子源存在下的对映选择性质子化中得到了探索。获得了α-取代的四氢萘酮的各种甲硅烷基烯醇醚的高度对映选择性质子化，以完全转化并具有高达99％的ee产生了手性α-取代的四氢萘酮。已建立的协议已成功扩展到生物相关的手性α-取代的苯并二氢吡喃酮和硫代苯并二氢吡喃酮衍生物的合成。
• Estrogen receptor modulators
  申请人：Parker LeRoy Dann

  公开号：US20060041003A1

  公开（公告）日：2006-02-23

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Pagets disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

  本发明涉及化合物及其衍生物，它们的合成以及它们作为雌激素受体调节剂的用途。本发明的化合物是雌激素受体的配体，因此可用于治疗或预防与雌激素功能相关的各种疾病，包括：骨质流失、骨折、骨质疏松症、转移性骨病、帕吉特病、牙周病、软骨退化、子宫内膜异位症、子宫肌瘤病、潮热、低密度脂蛋白胆固醇水平升高、心血管疾病、认知功能障碍、脑退行性疾病、再狭窄、男性乳腺发育、血管平滑肌细胞增殖、肥胖、失禁以及癌症，特别是乳腺、子宫和前列腺癌。
• Organic Compounds
  申请人：Barnes David

  公开号：US20080262050A1

  公开（公告）日：2008-10-23

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式(I)的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，例如SH2结构域。式(I)的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐症、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。这些疾病包括2型糖尿病的伴随症状，如高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及脂质代谢紊乱和其他胰岛素抵抗相关的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• Organic compounds
  申请人：Novartis AG

  公开号：US07700633B2

  公开（公告）日：2010-04-20

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为（I）的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可以用于治疗由PTPase活性介导的疾病。本发明的化合物也可以用作其他具有磷酸酪氨酸结合区域（如SH2结构域）特征的酶的抑制剂。公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗症，伴随2型糖尿病的病状，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤癌等，以及其他显示胰岛素抵抗的疾病。此外，本发明的化合物还可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。